Welcome to our dedicated page for Biostem Tech news (Ticker: BSEM), a resource for investors and traders seeking the latest updates and insights on Biostem Tech stock.
BioStem Technologies, Inc. (BSEM) delivers innovative regenerative medicine solutions through placental-derived allografts processed via its proprietary BioREtain® method. This page provides timely updates on clinical advancements, regulatory milestones, and operational developments critical to stakeholders in advanced wound care and MedTech.
Access official press releases covering clinical trial outcomes, product innovations, and strategic partnerships. Investors and healthcare professionals will find verified updates on FDA-cleared products, manufacturing expansions, and research collaborations that demonstrate BSEM’s commitment to improving patient outcomes.
All content is curated to meet rigorous compliance standards, with disclosures processed through BSEM’s AATB-accredited facilities. Bookmark this page for direct access to primary-source updates on BioStem’s progress in transforming wound care through biologically active therapies.
BioStem Technologies (OTC: BSEM) reported third quarter 2025 results on November 13, 2025, including net revenue of $10.5 million and GAAP net income of $0.8 million (earnings per share $0.05). The company reported adjusted EBITDA of $2.7 million and cash and cash equivalents of $27.2 million as of September 30, 2025.
Operational highlights included a 40% quarter-over-quarter product volume increase, positive randomized controlled trial results for BioREtain submitted to CMS, remediation of prior FDA inspection issues with a clean 361 inspection, appointment of KPMG, a land purchase for a new headquarters site, and a VA partnership to launch American Amnion in Q4.
BioStem Technologies (OTC: BSEM) announced it filed restated interim financial statements for Q1 2024–Q2 2025 and restated annual statements for 2023 and 2024.
The restatement reclassifies bona fide services fees under the distribution agreement with Venture Medical from Sales and Marketing expense to contra revenue, reducing reported gross revenue and Sales and Marketing expense by the same amount while leaving EBITDA, net income, and cash flow unchanged. Balance-sheet presentation now nets amounts payable to Venture against Accounts Receivable from Venture. The company said the restatement follows US GAAP review with external advisors and is intended to enable an independent audit by KPMG and a planned uplist; audits are expected complete by end of Q1 2026. The company noted that percentage metrics (gross margin, EBITDA margin) will appear slightly different under net revenue presentation.
BioStem (OTC: BSEM) commented on CMS’s CY 2026 Physician Fee Schedule final rule reforming Medicare reimbursement for skin substitutes announced Nov 5, 2025.
BioStem said the rule creates a more transparent, predictable reimbursement framework, though the reimbursement level is lower than the company advocated. The company highlighted a Level 1 randomized controlled trial showing superior patient outcomes for its BioREtain placental allografts and said that study was submitted to CMS. BioStem also said its proprietary, vertically integrated BioREtain manufacturing delivers materially lower COGS and scalable production, and expects margins to remain robust under the new model.
BioStem Technologies (OTC: BSEM) announced it purchased a four-acre parcel at the Research Park at Florida Atlantic University in Boca Raton to serve as its future headquarters for administrative offices, manufacturing, and distribution.
The City approved up to $300,000 in economic incentives tied to the creation of up to 100 jobs over five years. The company has not set a timetable for relocation. BioStem highlights its FDA-registered, AATB-accredited manufacturing site in Pompano Beach and its placental-derived wound-care product portfolio, including AmnioWrap 2 and VENDAJE brands.
BioStem Technologies (OTC: BSEM) reported top-line randomized controlled trial results published in the International Journal of Tissue Repair showing BioRetain (BR-AC) produced higher lasting wound-closure rates than standard of care in hard-to-heal diabetic foot ulcers (DFUs).
Key metrics: probability of lasting closure 53% for BR-AC vs 31% for standard of care over a 12-week period; study enrolled 71 patients across 11 U.S. sites, initiated Q4 2024, with lasting closure defined as remaining closed for 4 weeks. Future publications will report secondary endpoints including time to closure, wound area/volume change, and number of BR-AC applications.
BioStem Technologies (OTC: BSEM) will release its third quarter 2025 financial results on Thursday, November 13, 2025, and will host a conference call and webcast at 4:30 PM ET.
The webcast will feature an overview of the quarter from Jason Matuszewski, CEO, and Brandon Poe, CFO. Conference ID and dial-in numbers are provided for North America and international participants, and a live webcast link is available for online attendees.
BioStem Technologies (OTC: BSEM) announced that its Audit Committee approved the appointment of KPMG LLP as its independent registered public accounting firm, ending its engagement with Marcum (now CBIZ) effective Oct 22, 2025. The company said KPMG was selected for its life sciences expertise to support BioStem's growth and planned uplist to Nasdaq following completion of full-year 2024 and 2025 audits. Management emphasized the uplisting as a priority to improve liquidity, visibility, and market valuation. The company also stated there were no disagreements with Marcum during the two most recent fiscal years and any interim period before the dismissal.
BioStem Technologies (OTC: BSEM) has expanded its partnership with the Florida Panthers as the new sponsor of the "Heroes Among Us" program for its 13th season in 2025-26. The program, which has honored over 500 military veterans since 2013, recognizes one military hero at each Panthers home game with a national anthem dedication and video tribute.
BioStem will also continue supporting the "Seats for Service" program, which has provided 125 seats to veterans since the 2024-25 season. The initiative offers veterans four game tickets, parking, and a $50 food credit at Amerant Bank Arena. This partnership aligns with BioStem's upcoming launch of their American Amnion product line for military wound care and reflects the company's commitment to veterans, exemplified by their co-founder Andrew Van Vurst, a U.S. Marine Corps veteran.
BioStem Technologies (OTC: BSEM) announced its participation in the Symposium for Advanced Wound Care (SAWC) Fall meeting in Las Vegas from September 3-6, 2025. The company is co-exhibiting with strategic partner Venture Medical, LLC to showcase their combined wound care management solutions.
The exhibition features three scientific posters highlighting BioStem's proprietary BioREtain® technology and allograft portfolio. The company's leading products, AmnioWrap2® and Vendaje AC®, are exclusively available through Venture Medical and integrated with the Venture OneView™ platform for streamlined chronic wound care management.
The event includes scheduled booth presentations on wound care topics and a sponsored breakfast symposium titled "Navigating the Future of Wound Care," focusing on clinical evidence, allograft selection, and practice management.
BioStem Technologies (OTC:BSEM), a MedTech company specializing in placental-derived biologics for advanced wound care, has announced its participation in two upcoming investor conferences in New York.
The company will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 8, 2025, at 3:20 PM ET, followed by a presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 11:00 AM ET. Investors can access live and archived webcasts of both presentations through BioStem's investor relations website.
FAQ
What is the current stock price of Biostem Tech (BSEM)?
What is the market cap of Biostem Tech (BSEM)?
